Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration.

[1]  R. Avery.  Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52). , 2016, Ophthalmology.

[2]  R. Spaide,et al.  MULTIMODAL IMAGING FINDINGS AND MULTIMODAL VISION TESTING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2015, Retina.

[3]  Sandra S Stinnett,et al.  IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS , 2015, Retina.

[4]  Sina Farsiu,et al.  Kernel regression based segmentation of optical coherence tomography images with diabetic macular edema. , 2015, Biomedical optics express.

[5]  Milan Sonka,et al.  Stratified Sampling Voxel Classification for Segmentation of Intraretinal and Subretinal Fluid in Longitudinal Clinical OCT Data , 2015, IEEE Transactions on Medical Imaging.

[6]  A. Schachat,et al.  Optical coherence tomography, fluorescein angiography, and the management of neovascular age-related macular degeneration. , 2015, Ophthalmology.

[7]  Terje R Pedersen,et al.  Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. , 2015, Ophthalmology.

[8]  Giovanni Staurenghi,et al.  Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration , 2014, British Journal of Ophthalmology.

[9]  R. Gallego-Pinazo,et al.  Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs , 2014, Journal of ophthalmology.

[10]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[11]  Eric L Yuan,et al.  Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography. , 2014, Ophthalmology.

[12]  P. Wiedemann,et al.  Treatment patterns, visual acuity and quality‐of‐life outcomes of the WAVE study – A noninterventional study of ranibizumab treatment for neovascular age‐related macular degeneration in Germany , 2013, Acta ophthalmologica.

[13]  Gerard Mimoun,et al.  CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The LUMIERE Study , 2013, Retina.

[14]  Usha Chakravarthy,et al.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.

[15]  W. Freeman,et al.  HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.

[16]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[17]  Delia Cabrera DeBuc,et al.  A Review of Algorithms for Segmentation of Retinal Image Data Using Optical Coherence Tomography , 2011 .

[18]  Ghassan Hamarneh,et al.  Segmentation of Intra-Retinal Layers From Optical Coherence Tomography Images Using an Active Contour Approach , 2011, IEEE Transactions on Medical Imaging.